[1] Gashler AL, Swaminathan S, Sukhatme VP.  A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1[J]. Mol Cell Biol, 1993, 13(8): 4556-4571.
[2] Bickenbach KA, Veerapong J, Shao MY, et al.  Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy[J]. Cancer Gene Ther, 2008, 15(3): 133-139.   doi: 10.1038/sj.cgt.7701103
[3] Wang WD, Li R, Chen ZT, et al.  Cisplatin-controlled p53 gene therapy forhuman non-smallcelllung cancerxenografts in athymic nude mice via the CArG elements[J]. Cancer Sci, 2005, 96(10): 706-712.   doi: 10.1111/j.1349-7006.2005.00105.x
[4] Lucerna M, Pomyje J, Mechtcheriakova D, et al.  Sustained expression of early growth response protein-1 blocks angiogenesis and tumorgrowth[J]. CancerRes, 2006, 66(13): 6708-6713.
[5] Parra E, Ortega A, Saenz L.  Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3[J]. Oncol Rep, 2009, 22(6): 1513-1518.
[6] Tsurushima H, Yuan X, Dillehay LE, et al.  Radiation-inducible caspase-8 gene therapy for malignant brain tumors[J]. Int J Radiat OncolBiol Phys, 2008, 71(2): 517-525.   doi: 10.1016/j.ijrobp.2008.02.002
[7] Tsurushima H, Yuan X, Dillehay LE, et al.  Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors[J]. Cancer Gene Ther, 2007, 14(8): 706-716.   doi: 10.1038/sj.cgt.7701065
[8] Weichselbaum RR, Hallahan DE, Beckett MA, etal.  Gene therapy targeted by radiation preferentially radiosensitizes tumor cells[J]. Cancer Res, 1994, 54(16): 4266-4269.
[9] Hallahan DE, Qu S, Geng L, et al.  Radiation-mediated control of drug delivery[J]. Am J Clin Oncol, 2001, 24(5): 473-480.   doi: 10.1097/00000421-200110000-00012
[10] Senzer N, Mani S, Rosemurgy A, etal.  TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors[J]. J Clin Oncol, 2004, 22(4): 592-601.   doi: 10.1200/JCO.2004.01.227
[11] MacGill RS, Davis TA, Macko J, etal.  Localgene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response[J]. Clin Exp Metastasis, 2007, 24(7): 521-531.   doi: 10.1007/s10585-007-9089-3
[12] Kawashita Y, Ohtsuru A, Kaneda Y, etal.  Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation[J]. Hum Gene Ther, 1999, 10(9): 1509-1519.   doi: 10.1089/10430349950017842
[13] Hsu H, Rainov NG, Quinones A, et al.  Combined radiation and cytochrome CYP4Bl/4-ipomeanol gene therapy using the EGR1 promoter[J]. Anticancer Res, 2003, 23(3B): 2723-2728.
[14] Scott SD, Marples B, Hendry JH, et al.  A radiation-controlled molecular switch for use in gene therapy of cancer[J]. Gene Ther, 2000, 7(13): 1121-1125.   doi: 10.1038/sj.gt.3301223
[15] Jin GH, Jin SZ, Liu Y, et al.  Therapeutic effect of gene-therapy in combination with local X-irradiation in a mouse malignant melanoma model[J]. Biochem Biophys Res Commun, 2005, 330(3): 975-981.   doi: 10.1016/j.bbrc.2005.03.070
[16] Greco O, Marples B, Dachs GU, et al.  Novel chimeric gene promoters responsive to hypoxia and ionizing radiation[J]. Gene Ther, 2002, 9(20): 1403-1411.   doi: 10.1038/sj.gt.3301823
[17] Manome Y, Kunieda T, Wen PY, et al.  Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine[J]. Hum Gene Ther, 1998, 9(10): 1409-1417.   doi: 10.1089/hum.1998.9.10-1409
[18] Kawashita Y, Ohtsuru A, Miki F, et al.  Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodolinducible gene therapy[J]. Gene Ther, 2005, 12(22): 1633-1639.   doi: 10.1038/sj.gt.3302531
[19] Takahashi T, Namiki Y, Ohno T.  Induction of the suicide HSV-TK gene by activation of the Egr-1 promoter with radioisotopes[J]. Hum Gene Ther, 1997, 8(7): 827-833.   doi: 10.1089/hum.1997.8.7-827